VA106483 Dose Response in Females

This study has been completed.
Sponsor:
Information provided by:
Vantia Ltd
ClinicalTrials.gov Identifier:
NCT01171391
First received: July 19, 2010
Last updated: November 30, 2010
Last verified: November 2010

July 19, 2010
November 30, 2010
July 2010
November 2010   (final data collection date for primary outcome measure)
Pharmacokinetics [ Time Frame: 10 days ] [ Designated as safety issue: No ]
VA106483 plasma concentration pre-dose over a 24hr post-dose period to assess pharmacokinetics of each dose level
Same as current
Complete list of historical versions of study NCT01171391 on ClinicalTrials.gov Archive Site
  • Pharmacodynamics [ Time Frame: 10 days ] [ Designated as safety issue: No ]
    Urine volume and osmolality
  • Safety and Tolerability [ Time Frame: 10 days ] [ Designated as safety issue: Yes ]
    AEs, laboratory safety tests, vital signs and ECG, physical examination.
Same as current
Not Provided
Not Provided
 
VA106483 Dose Response in Females
An Open Label, Dose Escalation Study to Assess Intra-Subject Dose Response to VA106483 in Female Subjects

The purpose of this study is to describe the pharmacokinetics and pharmacodynamics of VA106483 in female subjects.

Nocturia, defined as waking to void at least once per night between periods of sleep, is a common complaint and shows an age-dependent increase in both prevalence and severity (number of nocturnal voids). The most common causes are detrusor over-activity, reduced nighttime functional bladder capacity, and nocturnal polyuria.

VA106483 is a selective vasopressin V2-receptor agonist in development for nocturia. VA106483 is a non-peptide drug that displays much improved oral availability over desmopressin and low dependence on glomerular filtration for its elimination.

VA106483 has been administered to 184 subjects (including healthy adult subjects [males and females], children [males and females] with nocturia and 48 elderly males [aged 65 years and over]). It has been administered as single doses both intravenously, up to doses of approximately 250 mg and orally up to 50 mg It is also being investigated in approximately 123 male subjects (two-thirds on active medication, one third on placebo) with nocturia in a current study with dosing for up to 8 weeks.

This intra-subject dose escalation study has previously been conducted in 10 elderly male subjects to determine whether subjects demonstrated a dose-dependent pharmacokinetic and pharmacodynamic (urine osmolality and diuresis) response and whether the dose of VA106483 could be titrated within an individual patient to achieve optimal clinical response in clinical practice. Given that to date, only 8 females have been exposed to VA106483, the purpose of this study is to confirm that the described duration of pharmacokinetics and pharmacodynamics of VA106483 in males is similar in females.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Nocturia
  • Drug: VA106483
    1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
  • Other: Placebo
    Placebo on Day 1
  • Experimental: VA106483 1mg
    Intervention: Drug: VA106483
  • Experimental: VA106483 2mg
    Intervention: Drug: VA106483
  • Experimental: VA106483 4mg
    Intervention: Drug: VA106483
  • Placebo Comparator: Sugar pill
    Intervention: Other: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
21
November 2010
November 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Female subjects 40 years and above
  • BMI 18 to 32 kg/m2
  • Using adequate contraception and providing negative pregnancy tests pre-dose
  • In good health as determined by medical history and screening tests
  • Subject is willing and able to abstain from alcohol and caffeine-containing food and beverages 72 hours prior to dosing and throughout the study
  • Provide written, informed consent

Exclusion Criteria:

  • Pregnancy or lactation
  • Evidence of serious pathology or diseases including heart, hormone, liver and kidney, psychiatric and neurological problems, including syndrome of inappropriate antidiuretic hormone secretion, polydipsia or diabetes insipidus
  • Likely to be hypersensitive to VA106483
  • History of any relevant allergy
  • Participation in a clinical study within 30 days
  • Donation of blood (500 mL) within 60 days prior to dosing
  • A history of alcohol abuse or drug addiction
  • Positive results for HIV, HBV or HCV or drugs of abuse
  • Currently taking any diuretics or clinically significant cytochrome 3A4 inhibitors or inducers
  • Use of any non-prescription preparation within 72 hours prior to dosing, with the exception of ibuprofen, and acetaminophen used at recommended doses
  • Treatment within the previous 3 months of drugs known to have a well defined potential for hepatoxicity
  • Current smokers or recent ex-smokers
  • Other protocol defined eligibility criteria may apply
Female
40 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01171391
483-007
No
Chief Medical Officer, Vantia Ltd
Vantia Ltd
Not Provided
Principal Investigator: Ralph Schutz Quintiles Phase I Services
Vantia Ltd
November 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP